These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35157291)

  • 21. VHH antibodies: emerging reagents for the analysis of environmental chemicals.
    Bever CS; Dong JX; Vasylieva N; Barnych B; Cui Y; Xu ZL; Hammock BD; Gee SJ
    Anal Bioanal Chem; 2016 Sep; 408(22):5985-6002. PubMed ID: 27209591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A single-domain antibody fragment in complex with RNase A: non-canonical loop structures and nanomolar affinity using two CDR loops.
    Decanniere K; Desmyter A; Lauwereys M; Ghahroudi MA; Muyldermans S; Wyns L
    Structure; 1999 Apr; 7(4):361-70. PubMed ID: 10196124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris.
    Rahbarizadeh F; Rasaee MJ; Forouzandeh M; Allameh AA
    Mol Immunol; 2006 Feb; 43(5):426-35. PubMed ID: 16337485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the Potential Impact of In Silico Humanization on V
    Martins C; Diharce J; Nadaradjane AA; de Brevern AG
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. VHH characterization.Recombinant VHHs: Production, characterization and affinity.
    Chabrol E; Stojko J; Nicolas A; Botzanowski T; Fould B; Antoine M; Cianférani S; Ferry G; Boutin JA
    Anal Biochem; 2020 Jan; 589():113491. PubMed ID: 31676284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Introduction to heavy chain antibodies and derived Nanobodies.
    Vincke C; Muyldermans S
    Methods Mol Biol; 2012; 911():15-26. PubMed ID: 22886243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the binding loops configuration and surface adaptation of different crystallized single-domain antibodies in response to various antigens.
    Al Qaraghuli MM; Ferro VA
    J Mol Recognit; 2017 Apr; 30(4):. PubMed ID: 27862476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Landscape of variable domain of heavy-chain-only antibody repertoire from alpaca.
    Tu Z; Huang X; Fu J; Hu N; Zheng W; Li Y; Zhang Y
    Immunology; 2020 Sep; 161(1):53-65. PubMed ID: 32506493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen.
    Dolk E; van Vliet C; Perez JM; Vriend G; Darbon H; Ferrat G; Cambillau C; Frenken LG; Verrips T
    Proteins; 2005 May; 59(3):555-64. PubMed ID: 15778955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural Classification of CDR-H3 in Single-Domain V
    Kuroda D; Tsumoto K
    Methods Mol Biol; 2023; 2552():61-79. PubMed ID: 36346585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies.
    van der Linden RH; Frenken LG; de Geus B; Harmsen MM; Ruuls RC; Stok W; de Ron L; Wilson S; Davis P; Verrips CT
    Biochim Biophys Acta; 1999 Apr; 1431(1):37-46. PubMed ID: 10209277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. V
    Vishwakarma P; Vattekatte AM; Shinada N; Diharce J; Martins C; Cadet F; Gardebien F; Etchebest C; Nadaradjane AA; de Brevern AG
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. VHH CDR-H3 conformation is determined by VH germline usage.
    Bahrami Dizicheh Z; Chen IL; Koenig P
    Commun Biol; 2023 Aug; 6(1):864. PubMed ID: 37598276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structural Basis of Epitope Recognition by Heavy-Chain Camelid Antibodies.
    Zavrtanik U; Lukan J; Loris R; Lah J; Hadži S
    J Mol Biol; 2018 Oct; 430(21):4369-4386. PubMed ID: 30205092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon.
    Paalanen MM; Ekokoski E; El Khattabi M; Tuominen RK; Verrips CT; Boonstra J; Blanchetot C
    Eur J Pharm Sci; 2011 Mar; 42(4):332-9. PubMed ID: 21220006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies.
    De Genst E; Silence K; Decanniere K; Conrath K; Loris R; Kinne J; Muyldermans S; Wyns L
    Proc Natl Acad Sci U S A; 2006 Mar; 103(12):4586-91. PubMed ID: 16537393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stimulation of chymosin secretion by simultaneous expression with chymosin-binding llama single-domain antibody fragments in yeast.
    Harmsen MM; Smits CB; de Geus B
    Appl Microbiol Biotechnol; 2002 Dec; 60(4):449-54. PubMed ID: 12466886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Llama VHH antibody fragments against GFAP: better diffusion in fixed tissues than classical monoclonal antibodies.
    Perruchini C; Pecorari F; Bourgeois JP; Duyckaerts C; Rougeon F; Lafaye P
    Acta Neuropathol; 2009 Nov; 118(5):685-95. PubMed ID: 19597828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanobodies: natural single-domain antibodies.
    Muyldermans S
    Annu Rev Biochem; 2013; 82():775-97. PubMed ID: 23495938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular recognition requires dimerization of a VHH antibody.
    Smith CA; Sonneson GJ; Hoey RJ; Hinerman JM; Sheehy K; Walter R; Herr AB; Horn JR
    MAbs; 2023; 15(1):2215363. PubMed ID: 37243579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.